Form 4 for FDMT 4D Molecular Therapeutics, Inc.
Accepted 2026-09-16 17:13:54 ET · period of report 2026-09-14 · accession 0001193125-26-393243 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-09-16 17:13 | 2026-09-14 | FDMT | Kirn David | See Remarks, Dir | S - Sale | $13.90 | -58.3K | 767.5K | -7% | -$811.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-14 | S | D | 58,333 | $13.90 | 767,486 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026. (F2) The transaction was executed in multiple trades in prices ranging from $13.43 to $14.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |